Human immunoglobulin versus plasmapheresis in guillain-barre syndrome and myasthenia gravis: A meta-analysis
Objectives: To evaluate the efficacy and safety over a short time period of human intravenous immunoglobulin versus plasma exchange (PE) in the management of some autoimmune neurologic diseases. In addition, length of hospital stay and duration of ventilator support were compared. Methods: Randomize...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2016
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/22304
- Acceso en línea:
- https://doi.org/10.1097/CND.0000000000000119
https://repository.urosario.edu.co/handle/10336/22304
- Palabra clave:
- Albumin
Human immunoglobulin
Immunoglobulin
Acute kidney failure
Allergic reaction
Anemia
Article
Artificial ventilation
Body weight
Chill
Diarrhea
Disability
Drug efficacy
Drug safety
Dyspnea
Faintness
Fever
Guillain barre syndrome
Headache
Heart arrhythmia
Hematoma
Hematuria
Hemolytic anemia
Human
Hypertension
Hypertransaminasemia
Hypocalcemia
Hypotension
Length of stay
Meningism
Meta analysis
Muscle weakness
Myasthenia gravis
Nausea and vomiting
Phlebitis
Plasmapheresis
Pneumonia
Priority journal
Randomized controlled trial (topic)
Rash
Sensitivity analysis
Sepsis
Systematic review
Treatment outcome
Vasospasm
Vein thrombosis
Vertigo
Comparative study
Guillain-barre syndrome
Myasthenia gravis
Plasmapheresis
Procedures
Guillain-barre syndrome
Humans
Myasthenia gravis
Plasmapheresis
Randomized controlled trials as topic
Treatment outcome
Adverse effects
Autoimmune neurologic diseases
Efficacy
Immunoglobulin
Plasma exchange
intravenous
Immunoglobulins
- Rights
- License
- Abierto (Texto Completo)
Summary: | Objectives: To evaluate the efficacy and safety over a short time period of human intravenous immunoglobulin versus plasma exchange (PE) in the management of some autoimmune neurologic diseases. In addition, length of hospital stay and duration of ventilator support were compared. Methods: Randomized controlled trials and analytical observational studies of more than 10 cases were reviewed. Cochrane Neuromuscular Disease Group trials, MEDLINE, EMBASE, HINARI, and Ovid, were searched as data source. Reference lists were examined for further relevant articles. A random-effect model was used to derive a pooled risk ratio. Results: A total of 552 articles were found and 24 met the criteria for a studied population of 4657 cases: 14 articles were about Guillain-Barré syndrome and 10 of myasthenia gravis. No evidence was found to suggest that PE or intravenous immunoglobulin differed in terms of efficacy or safety to treat any of the 2 diseases. Hospital stay length and ventilatory support time are different in each illness; however, we found no statistical difference in either of the 2 treatments. Conclusions: There is no evidence for superiority in the efficacy or safety of immunoglobulin or plasmapheresis in the management of Guillain-Barré syndrome and myasthenia gravis. However, caution should be exercised in the interpretation of these results given the limitations in the quality of the evidence and the heterogeneity of the studies. © 2016 Wolters Kluwer Health, Inc. All rights reserved. |
---|